bioAffinity Technologies Inc./$BIAF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Ticker
$BIAF
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
57
ISIN
US09076W1099
Website
BIAF Metrics
BasicAdvanced
$8.3M
-
-$0.71
2.56
-
Price and volume
Market cap
$8.3M
Beta
2.56
52-week high
$1.55
52-week low
$0.16
Average daily volume
6.3M
Financial strength
Current ratio
0.546
Quick ratio
0.412
Long term debt to equity
48.108
Total debt to equity
92.48
Interest coverage (TTM)
-114.15%
Management effectiveness
Return on assets (TTM)
-88.58%
Return on equity (TTM)
-290.85%
Valuation
Price to revenue (TTM)
0.472
Price to book
3.75
Price to tangible book (TTM)
-7.44
Price to free cash flow (TTM)
-0.625
Growth
Revenue change (TTM)
78.40%
Earnings per share change (TTM)
-22.59%
3-year earnings per share growth (CAGR)
-35.49%
BIAF News
AllArticlesVideos
bioAffinity Technologies Announces Closing of $3.25 Million Offering
Business Wire·4 weeks ago
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
Business Wire·2 months ago
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for bioAffinity Technologies Inc. stock?
bioAffinity Technologies Inc. (BIAF) has a market cap of $8.3M as of June 06, 2025.
What is the P/E ratio for bioAffinity Technologies Inc. stock?
The price to earnings (P/E) ratio for bioAffinity Technologies Inc. (BIAF) stock is 0 as of June 06, 2025.
Does bioAffinity Technologies Inc. stock pay dividends?
No, bioAffinity Technologies Inc. (BIAF) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next bioAffinity Technologies Inc. dividend payment date?
bioAffinity Technologies Inc. (BIAF) stock does not pay dividends to its shareholders.
What is the beta indicator for bioAffinity Technologies Inc.?
bioAffinity Technologies Inc. (BIAF) has a beta rating of 2.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.